Claude Maraoui: FY25 Revenue at $61.9M
Reports FY25 revenue $61.9M, consensus $64.7M. Claude Maraoui, CEO, said, "We delivered a year of meaningful commercial progress, highlighted by the successful launch and rapid uptake of Emrosi(TM), which is driving solid revenue growth and expanding our presence in medical dermatology. Our financial performance continues to strengthen with rising net product revenues, improving gross margins and expense optimization, supported by disciplined investment in our dermatology focused sales infrastructure. Emrosi(TM) achieved strong prescription momentum and broader payer access throughout the year, and its differentiated clinical profile further reinforces our confidence in the product's long-term potential as a key growth driver for our Company. As we look ahead to 2026 and beyond, we remain well-positioned to continue to execute on our strategy, leveraging our commercial platform to drive improving financial performance, and advancing innovative therapies that address important needs for patients with dermatologic conditions, while increasing value for our shareholders."
Trade with 70% Backtested Accuracy
Analyst Views on DERM
About DERM
About the author
Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
Journey Medical Reports FY 2025 Financial Results with Mixed Performance
- Revenue Growth: Journey Medical reported FY 2025 revenue of $61.6 million, reflecting a 9.7% year-over-year increase, although it missed analyst expectations by $3.05 million, indicating volatility in market demand.
- Gross Margin Improvement: The gross margin for FY 2025 improved to 66.2% from 62.8% in FY 2024, driven by increased sales of higher-margin products like Emrosi™ and Qbrexza®, showcasing the company's success in optimizing its product mix.
- Increase in SG&A Expenses: Selling, general, and administrative expenses rose to $44.4 million in FY 2025, a 10% increase from $40.2 million in FY 2024, primarily due to incremental operational activities related to the launch and commercialization of Emrosi™, which may impact future profitability.
- Reduction in Net Loss: The net loss for FY 2025 was $11.4 million, or $0.47 per share, an improvement from a net loss of $14.7 million, or $0.72 per share in FY 2024, indicating the company's efforts in cost control and efficiency enhancement.
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
Journey Medical Reports FY 2025 Financial Results with Mixed Performance
- Revenue Growth: Journey Medical reported FY 2025 revenue of $61.6 million, reflecting a 9.7% year-over-year increase, although it missed analyst expectations by $3.05 million, indicating volatility in market demand.
- Gross Margin Improvement: The gross margin for FY 2025 improved to 66.2% from 62.8% in FY 2024, driven by increased sales of higher-margin products like Emrosi™ and Qbrexza®, showcasing the company's success in optimizing its product mix.
- Increase in SG&A Expenses: Selling, general, and administrative expenses rose to $44.4 million in FY 2025, a 10% increase from $40.2 million in FY 2024, primarily due to incremental operational activities related to the launch and commercialization of Emrosi™, which may impact future profitability.
- Reduction in Net Loss: The net loss for FY 2025 was $11.4 million, or $0.47 per share, an improvement from a net loss of $14.7 million, or $0.72 per share in FY 2024, indicating the company's efforts in cost control and efficiency enhancement.
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
